Point: Impact of prostate-specific antigen velocity on management decisions and recommendations

Research output: Contribution to journalArticle

Abstract

Prostate-specific antigen (PSA) velocity predicts the presence of prostate cancer on biopsy and a greater risk of prostate cancer death after radical treatment. A new variation on PSA velocity called the risk count was recently shown to provide incremental reclassification for intermediate to high-grade disease on biopsy beyond PSA and age. These markers therefore have the potential to reduce overdiagnosis and overtreatment of indolent prostate cancer, and several professional guidelines support the use of PSA kinetics along with other predictors as part of the diagnostic algorithm. Among men already diagnosed with prostate cancer, PSA kinetics may also be helpful in predicting prognosis after definitive therapy.

Original languageEnglish (US)
Pages (from-to)281-285
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume11
Issue number3
DOIs
StatePublished - Mar 1 2013

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Point: Impact of prostate-specific antigen velocity on management decisions and recommendations'. Together they form a unique fingerprint.

  • Cite this